Researchers at ETH Zurich have identified a new chemical compound, dubbed “Compound 10,” that shows potential in slowing the progression of Alzheimer’s disease by targeting the enzyme GRK2. According to findings published in Cell Reports Medicine, the substance prevents the formation of harmful enzyme aggregates in brain cells, offering a distinct mechanism compared to existing treatments.
How Does Compound 10 Target Alzheimer’s?
The research, led by Professor of Molecular Pharmacology Ursula Quitterer at ETH Zurich, focuses on a bodily enzyme called GRK2. While this protein is essential for helping cells respond to stress, Quitterer’s team discovered that an inactivated form of GRK2 accumulates in the brain tissue of dementia patients. These aggregates deposit on mitochondria, the “powerhouses” of the cell, blocking their pores and restricting energy supply. According to Quitterer, this creates a “vicious circle” where the resulting cellular stress promotes the production of amyloid beta, a protein fragment central to Alzheimer’s pathology.
Did you know? The research process for this discovery spanned nearly 20 years. It began with the analysis of human brain tissue samples obtained from tumor surgeries at Ain Shams University Hospital in Cairo.
Can This Treatment Reverse Aging?
Beyond its impact on dementia, Compound 10 demonstrated broader biological effects in mouse models. Quitterer’s team observed that the active ingredient not only protected nerve cells—leading to longer survival rates in the animals—but also influenced external aging processes. Notably, the treated mice exhibited fewer grey hairs in old age and showed improvements in heart function. This dual impact suggests that the underlying mechanisms of GRK2 aggregation are tied to broader cellular health and the aging process.
Why Does Alzheimer’s Research Take So Long?
Developing treatments for age-related neurodegeneration is inherently slow. Quitterer notes that because the research involves older animals—specifically mice aged one and a half to two years—each experimental cycle requires a significant time investment. Compared to fields like cancer research, where conclusions can be drawn more rapidly, Alzheimer’s studies are limited by the biological timeline of the disease. The current study, published in 2026, represents the completion of basic research, with the team now seeking industry partners to move toward drug development.
Frequently Asked Questions
- How is Compound 10 different from current Alzheimer’s drugs?
Existing medications generally only delay progression by a few months. Compound 10 targets a specific protein, GRK2, using a mechanism distinct from currently approved therapies. - What is the role of GRK2 in the brain?
GRK2 is a regulatory protein that helps nerve cells respond to signals and stress. In dementia patients, it becomes inactivated and forms aggregates that damage mitochondria. - Is Compound 10 available for patients?
No. The research is currently in the basic stage, and ETH Zurich is searching for a commercial partner to facilitate further development.
Stay Informed
We are tracking the latest developments in neurodegenerative research. Subscribe to our newsletter for updates on the clinical transition of Compound 10 and other breakthroughs in molecular pharmacology.
